Richard Harris

Pfizer may now start shipping the inoculation to hospitals across the country. Health care workers and people in nursing homes and assisted living centers will be given priority for the vaccine.

Pfizer's COVID-19 vaccine may have side effects that can sometimes knock people out of work for a day or so. Hospitals are planning vaccine campaigns for their workers to avoid staff shortages.

A Food and Drug Administration advisory committee is preparing to vote on whether to recommend Pfizer's COVID-19 vaccine for emergency use in the United States.

In a 17-4 vote, an expert committee concluded that the scientific evidence supports the authorization of the COVID-19 vaccine from Pfizer and BioNTech for emergency use during the pandemic.

A federal advisory committee is evaluating Pfizer's COVID-19 vaccine. The Food and Drug Administration will weigh that input as it decides whether to grant emergency use for the vaccine.

In the midst of grim COVID-19 news this week there is some hope on vaccines. The FDA will review the Pfizer vaccine this coming Thursday and it could be authorized almost immediately.

The United Kingdom has become the first country to approve a thoroughly tested COVID-19 vaccine. A British regulatory agency approved the Pfizer/BioNTech vaccine on Wednesday.

Drugmaker Moderna says it has applied to the Food and Drug Administration for emergency use authorization for its coronavirus vaccine. It says data bolster its case the vaccine is safe and effective.

The biotech company has new data reinforcing that its COVID-19 inoculation is safe and effective. Moderna is submitting an application to the FDA requesting emergency use authorization.

The medicines from Eli Lilly and Regeneron are infused, a process that can take two hours or longer, including observation for side effects. Staffing is as big an issue as the supply of the drugs.

Hospitals are figuring out how to administer drugs that are designed to treat people with mild to moderate COVID-19 symptoms. The drugs are in short supply, and there is no guarantee they will work.

The race to develop COVID-19 vaccines is moving swiftly, both nationally and internationally. But challenges remain when it comes to distributing vaccines around the world.

A new medication to treat COVID patients will be available next week, but it requires an IV and is in short supply.

As coronavirus cases surge across the United States, a second vaccine candidate is said to show great promise. Experts say the first vaccines could become available as early as late December.

Eli Lilly's monoclonal antibody will be available to people 65 or older or those with underlying health conditions. Supplies will be short, and allocating the medicine will be a challenge.

The federal government plans to distribute 300,000 doses of the drug at no cost, but that doesn't mean treatment will be free. Intravenous infusion charges can run more than $1,000.

Experimental medicines have the potential to help people with COVID-19 avoid hospitalization. The scarce supply of the treatments would have to be rationed, if regulators OK their use.

COVID-19 antibody drugs appear to be helping people avoid hospitalization. Tens of thousands of people a day could be candidates to take the drugs, but the scarce supply has to be rationed.

Pfizer announced Friday there would be no coronavirus vaccine before the election. And a new study questioned the effectiveness of remdesivir, a drug used to treat hospitalized COVID-19 patients.

Pfizer Chairman and CEO Albert Bourla said in a public statement Friday that the company won't have data showing that the vaccine is safe before the third week of November at the earliest.